Early toxicity testing is used during clinical trials, where the toxicity of the compounds present in the test product is evaluated. Different tests are conducted to check the adverse effects of the compound on different aspects of human health. Some tests are also useful to check if the entity has toxic potentials such as genotoxicity, carcinogenicity, neurotoxicity, and systemic toxicity. These toxicity tests are important for the welfare of human health and environment.
Early Toxicity Testing Market is anticipated to reach $1,012 million by 2022, registering a CAGR of 7.3% during the forecast period, 2016 to 2022, according to a new report published by Allied Market Research. Among different geographic regions, Europe is the largest contributor toward the early toxicity testing market; whereas, Asia-Pacific is the fastest growing region.
The increase in awareness among the regulatory authorities concerning environment and human health welfare is the major factor that fuels the growth of this market. The early toxicity testing market experienced moderate growth in the recent years due to the replacement of in vivo models by in vitro models and technological advancement in in vitro and in silico techniques. However, certain limitations of preclinical trials and limited awareness about the benefits of using early toxicity tests are estimated to hamper the market growth.
The global early toxicity testing market is segmented based on technique, end users, and geography. Based on technique, the market is categorized into in vivo, in vitro, and in silico. Based on the type of assay used, in vitro technique is further divided into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA and western blots, tissues culture assays, receptor binding assays, and other assays. Based on the toxicity end-points, in vitro technique is further segmented into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, genotoxicity, neurotoxicity, organ toxicity, and other toxicity endpoints. Based on end-users, the market is segmented into pharmaceuticals industry, diagnostics industry, food industry, chemicals industry, cosmetics industry, and other industries. The market is analyzed based on four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
Get the PDF brochure of this market insight@ https://www.alliedmarketresearch.com/request-sample/619
The market is expected to witness moderate growth during the forecast period, owing to the increase in awareness of the regulatory authorities concerning environment and public health welfare. In addition, replacement of in vivo models with in vitro models and technological advancement in the in vitro and in vivo technique supplement the market growth. As early toxicity tests can help reduce the risk of drug failure in later stages, there is a rise in the demand for early toxicity tests. This has increased investment in the R&D for these products, which help boost the market growth. However, limited awareness about the benefits of early toxicity testing and limitations of preclinical testing are expected to hamper the market growth.
Key Findings of the Early Toxicity Testing Market
- Genotoxicity is projected to be the fastest growing segment during the analysis period.
- Pharmaceutical industry was the highest revenue contributor by end users and is expected to continue its dominance throughout the forecast period.
- Europe dominated global early toxicity testing market and is projected to grow at a CAGR of 6.6%.
- China is the fastest growing country in the Asia-Pacific region, registering a CAGR of 15.8% from 2016 to 2022.
- Cosmetic industry segment exhibits fast paced growth rate registering a CAGR of 9.8%.